Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy

被引:13
作者
Monty, Masuma Akter [1 ]
Islam, Md. Ariful [2 ]
Nan, Xu [1 ]
Tan, Jingwen [1 ]
Tuhin, Israth Jahan [1 ]
Tang, Xiaowen [3 ]
Miao, Miao [3 ]
Wu, Depei [3 ]
Yu, Lei [1 ]
机构
[1] East China Normal Univ, Sch Chem & Mol Engn, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Inst Biomed Engn & Technol, Shanghai 200062, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China
关键词
cancer immunotherapy; combinatorial RNAi; gene silencing; RNA interference (RNAi); RNAi‐ mediated immunotherapy; T cell; vector;
D O I
10.1111/bph.15414
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNAi effectors (e.g. siRNA, shRNA and miRNA) can trigger the silencing of specific genes causing alteration of genomic functions becoming a new therapeutic area for the treatment of infectious diseases, neurodegenerative disorders and cancer. In cancer treatment, RNAi effectors showed potential immunomodulatory actions by down-regulating immuno-suppressive proteins, such as PD-1 and CTLA-4, which restrict immune cell function and present challenges in cancer immunotherapy. Therefore, compared with extracellular targeting by antibodies, RNAi-mediated cell-intrinsic disruption of inhibitory pathways in immune cells could promote an increased anti-tumour immune response. Along with non-viral vectors, DNA-based RNAi strategies might be a more promising method for immunomodulation to silence multiple inhibitory pathways in T cells than immune checkpoint blockade antibodies. Thus, in this review, we discuss diverse RNAi implementation strategies, with recent viral and non-viral mediated RNAi synergism to immunotherapy that augments the anti-tumour immunity. Finally, we provide the current progress of RNAi in clinical pipeline.
引用
收藏
页码:1741 / 1755
页数:15
相关论文
empty
未找到相关数据